Erythema multiforme caused by topical imiquimod 3.75%

César Magalhães, Dermatology Service, Centro Hospitalar Vila Nova de Gaia/Espinho, Porto, Portugal André Coelho, Pathological Anatomy Laboratory, Unilabs. Porto, Portugal Miguel Costa, Dermatology Service, Centro Hospitalar Vila Nova de Gaia/Espinho, Porto, Portugal Nuno Menezes, Dermatology Service, Centro Hospitalar Vila Nova de Gaia/Espinho, Porto, Portugal

Imiquimod, 3.75% cream, is a topical immunomodulator approved for treating actinic keratoses. Although local side effects are more frequent, it can also have systemic side effects. We report that imiquimod 3.75% can also produce erythema multiforme (EM), thus discarding it as an alternative to imiquimod 5% on this adverse effect.